Eledon reports updated data from ongoing phase 1b trial evaluating tegoprubart for prevention of rejection in kidney transplantation

Data from 11 participants demonstrates tegoprubart successfully prevented kidney transplant rejection and was generally safe and well-tolerated aggregate mean egfr was above 70 ml/min/1.73m 2 at all reported time points after day 90 supporting tegoprubart's potential to protect organ function in patients undergoing kidney transplantation eledon will host a conference call today at 5:00 p.m. et irvine, calif.
ELDN Ratings Summary
ELDN Quant Ranking